MARLBOROUGH, Mass.--(BUSINESS WIRE)-- <\/p>\n
Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the Keynote Address at the BWH Regenerative Medicine Center Inaugural Symposium, being held at Brigham & Womens Hospital in Boston on June 11. The Symposium will showcase an exciting array of research in regenerative medicine; highlighting the work of both nationally and internationally recognized investigators and that of the rising stars working in this domain. Dr. Lanzas address, titled Pluripotent Stem Cells Moving From Bench to Bedside, will take place at 4 p.m. EDT in the Bornstein Family Amphitheater & Cabot Atrium. <\/p>\n
The newly formed Regenerative Medicine Center at Brigham & Womens Hospital is a marriage of stem cell biology with state-of-the-art engineering and nanotechnology, integrating the talents of engineers, physicists and mathematicians with those of biologists and clinicians. BWH investigators are nationally and internationally recognized for their contributions to advances in stem cell, regenerative medicine and tissue engineering research as recipients of prestigious awards, including elected members of numerous scientific and medical organizations. In addition to Dr. Lanzas Keynote Address, the Symposium will include sessions about Pluripotent Stem Cells & Basic Developmental Biology, Adult Stem Cells & Disease and Novel Technologies in Regenerative Medicine. <\/p>\n
About Advanced Cell Technology, Inc. <\/p>\n
Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http:\/\/www.advancedcell.com<\/a>. <\/p>\n Forward-Looking Statements <\/p>\n Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful. <\/p>\n<\/p>\n <\/p>\n Read the original: <\/p>\n ACT\u2019s Dr. Robert Lanza to Deliver the Keynote Address at Brigham & Women\u2019s Hospital Regenerative Medicine Center ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the Keynote Address at the BWH Regenerative Medicine Center Inaugural Symposium, being held at Brigham & Womens Hospital in Boston on June 11. The Symposium will showcase an exciting array of research in regenerative medicine; highlighting the work of both nationally and internationally recognized investigators and that of the rising stars working in this domain. Continue reading